CERS

CERUS CORP

2.19^post+$0.00 (+0.00%)at close +$0.00 (+0.00%)

tap the star to start your desk

as of 19:59:56 UTCnext report Nov 3 · 90d

Performance

3M−15.44%

Relationships

11 ties · EDGAR · select for source

CERS

CERS buys fromCERS sells to

what am I seeing?

Nodes sit closer to CERS when the tie is more firmly disclosed — a named revenue weight first, then high-confidence ties, then the rest. A node's glow tracks its move today: it lifts (green) when up, sinks (red) when down, and brightens with the size. Select any node for the filing sentence behind the tie.

etf exposure · n-port

ARKK0.30%IWM0.01%VTI0.00%

Earnings

consensus

Next reportNov 3 · in 90d · after close

has moved

±14.6%

per session, last 8 reports

market-implied

±25.2%

to the next expiry after this report

Open the Earnings Roomthe report · expected movement · blast radius · the record

Earnings

loading…

Event sensitivity

computed

FOMCrate decisionup 8 of 24±3.8%1.1×

NFPjobs reportup 2 of 7±3.7%1.1×

PCEpersonal income & outlaysup 8 of 17±3.4%1.0×

GDPgross domestic productup 8 of 17±2.9%0.9×

PPIproducer pricesup 6 of 8±2.8%0.8×

CPROFcorporate profitsup 5 of 10±2.7%0.8×

CPIconsumer pricesup 4 of 8±2.6%0.8×

How CERS has moved on past release days vs its typical ±3.4% day, and how often it closed up. Computed from daily closes — not a forecast.

Event sensitivity

loading…

News

1 story · wire

CERS5dCERUS CORP — 8-K filed · Item 2.02, 9.01 · SEC

News

loading…

Overview

Medical Equipment

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

sector: Manufacturing
chief executive: William M. Greenman
employees: 290
headquarters: California · United States of America
listed: Nasdaq
web: cerus.com

Overview

loading…